CTII could have a key to treating neurological diseases and injuries, but it is still a long way from a product. If the stock moves higher, sell part of your position on a scale up. Demegen is one of the most prolific patent reapers among small companies. Recently it was awarded patents related to wound healing and to synthetic peptides as treatments for cancer and other diseases. We like the prospects, but research continues to be restricted by limited working capital.
Management does always come up with enough cash to keep going.
This stock has been up and down so often that we would treat it as a trading vehicle, selling some on further strength. P-Com is another stock that s come to life based on current Internet and telecommunications excitement. Wireless communications is already a major growth industry and it will get bigger as carriers use wireless to fill gaps in their networks and as cell phones morph into data terminals. But there s strong competition, which has slowed P-Com. A recent strategic agreement with HeliOss Communications will broaden the product line and help gain market share.